Patents by Inventor May H. Han

May H. Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8828668
    Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: September 9, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Robert C. Axtell, Lawrence Steinman, May H. Han, Brigit A. de Jong, Chander Raman, Michael Walker, Jing Shi
  • Patent number: 8257700
    Abstract: The invention provides methods for treating demyelinating inflammatory diseases by administering to the subject an effective amount of an agent that provides activated protein C activity, where the dose is effective to reduce the adverse clinical indicia of the disease. In some embodiments, the patient being treating is of the chronic active plaque type.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: September 4, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lawrence M. Steinman, May H. Han
  • Publication number: 20110250206
    Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.
    Type: Application
    Filed: February 11, 2011
    Publication date: October 13, 2011
    Inventors: Robert C. Axtell, Lawrence Steinman, May H. Han, Brigit A. de Jong, Chander Raman, Michael Walker, Jing Shi, Tito A. Serafini
  • Publication number: 20110243893
    Abstract: Compositions and methods are provided for prognostic classification of inflammatory diseases, e.g. inflammatory demyelinating disease, patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Assessment of this signature pattern thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is multiple sclerosis or neuromyelitis optica.
    Type: Application
    Filed: February 11, 2011
    Publication date: October 6, 2011
    Inventors: Robert C. Axtell, Lawrence Steinman, May H. Han, Brigit A. de Jong, Chander Raman, Michael Walker, Jing Shi
  • Publication number: 20090208481
    Abstract: The invention provides methods for treating demyelinating inflammatory diseases by administering to the subject an effective amount of an agent that provides activated protein C activity, where the dose is effective to reduce the adverse clinical indicia of the disease. In some embodiments, the patient being treating is of the chronic active plaque type.
    Type: Application
    Filed: February 5, 2009
    Publication date: August 20, 2009
    Inventors: Lawrence M. Steinman, May H. Han